Patents by Inventor Assia Angelova

Assia Angelova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
    Patent number: 11964015
    Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: April 23, 2024
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Barbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
  • CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITOR
    Publication number: 20210228714
    Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
    Type: Application
    Filed: April 9, 2021
    Publication date: July 29, 2021
    Inventors: Barbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
  • Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
    Patent number: 11027013
    Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: June 8, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Barbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
  • CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITOR
    Publication number: 20190117768
    Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
    Type: Application
    Filed: October 1, 2018
    Publication date: April 25, 2019
    Inventors: Barbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
  • Parvovirus cancer therapy and combination with chemotherapy
    Patent number: 8414883
    Abstract: Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: April 9, 2013
    Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg
    Inventors: Jean Rommelaere, Zahari Raykov, Joerg Schlehofer, Irina Kiprijanova, Tanja Heimberger, Assia Angelova, Karsten Geletneky, Marc Aprahamian
  • Parvovirus Cancer Therapy and Combination with Chemotherapy
    Publication number: 20110020287
    Abstract: Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.
    Type: Application
    Filed: December 23, 2008
    Publication date: January 27, 2011
    Inventors: Jean Rommelaere, Zahari Raykov, Joerg Schlehofer, Irina Kiprijanova, Tanja Heimberger, Assia Angelova, Karsten Geletneky, Marc Aprahamiam